B. Nguyen

发表

FLT3/ITD Expression Increases Expansion, Survival and Entry into Cell Cycle of Human Hematopoietic Stem Cells.

Kyu-Tae Kim, M. Levis, D. Small, 2004 .

CRISPR-Cas13d for Gene Knockdown and Engineering of CHO Cells.

Yu-Chen Hu, Mei-Wei Lin, Chih-Che Shen, 2020, ACS synthetic biology.

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.

D. Hicklin, D. Huso, D. Small, 2006, Cancer research.

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3

M. Levis, D. Small, A. Duffield, 2018, Oncotarget.

Further Activation of FLT3 Mutants by FLT3 Ligand

M. Levis, D. Small, Xiaochuan Yang, 2011, Oncogene.

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

P. Calabresi, D. Pardoll, D. Small, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Statin Treatment Inhibits FLT3 Signaling by Preventing Glycosylation of the Mature Receptor and Leads to Cell Death In Mutant FLT3 Expressing Cells

M. Levis, D. Small, P. Brown, 2010 .

Title A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors

Jun O. Liu, M. Levis, D. Small, 2021 .

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

M. Rudek, M. Levis, D. Small, 2014, Blood.

FLT3-associated leukemias in vitro and in vivo TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against

R. Ribeiro, M. Levis, A. Duffield, 2014 .

A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors

Jun O. Liu, M. Levis, D. Small, 2021, Blood cancer discovery.

A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.

Jun O. Liu, M. Levis, D. Small, 2021, Cancer discovery.

MYELOID NEOPLASIA All- trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD 1 leukemia stem cells in vitro and in vivo

Richard J. Jones, D. Small, A. Duffield, 2016 .

All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.

Richard J. Jones, D. Small, A. Duffield, 2016, Blood.

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

M. Levis, D. Small, D. Leahy, 2013, Leukemia.

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

M. Levis, D. Small, David J. Young, 2017, Oncotarget.

Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.

M. Levis, D. Small, P. Brown, 2012, Blood.

Fluvastatin inhibits FLT 3 glycosylation in human and murine cells and prolongs survival of mice with FLT 3 / ITD leukemia

M. Levis, D. Small, P. Brown, 2012 .

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

M. Levis, D. Small, B. Nguyen, 2017, Blood.

Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.

S. Desiderio, M. Borowitz, D. Huso, 2012, Blood.

Gilteritinib and Venetoclax Synergize to Eliminate FLT3/ITD+ Leukemia Cells through BIM

D. Small, A. Duffield, Li Li, 2019, Blood.

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

M. Levis, D. Small, A. Duffield, 2021, Signal Transduction and Targeted Therapy.

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

M. Levis, D. Small, D. Leahy, 2014, Cancer research.

Therapeutics , Targets , and Chemical Biology FLT 3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT 3 in Acute Myeloid Leukemia

Eld, M. Levis, D. Small, 2014 .

Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model

D. Small, A. Duffield, C. Gamper, 2016, Oncotarget.

PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Ky-Youb Nam, D. Small, Li Li, 2020 .